ArticleScience immunology2021
Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 77 citations in OpenAlex.
- Neutrophil-hybrid CAR-macrophages bring double trouble to tumors.Nature immunology · 2026Article
- Integrated single-cell multiomics reveals neutrophil-driven immune-metabolic reprogramming of Kupffer cells via thrombospondin-1/CD36 after surgical stress.JCI insight · 2026Article
- Review
- Article
- Single-cell transcriptomics showed that maternal polychlorinated biphenyl exposure dysregulated cell type-specific metabolic responses in the livers of female mouse offsprings.Drug metabolism and disposition: the biological fate of chemicals · 2026Article
- Positioning and reversible suppression of CCR7Immunity · 2026Article
- Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1Nature communications · 2025Article
- Targeting Myeloid Cells for Cancer Immunotherapy.Cancer immunology research · 2025Review
- Comparative efficacy and safety of PD-1/PD-L1 inhibitors versus docetaxel in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab.Translational lung cancer research · 2025Article
- Heterogeneous tissue-specific macrophages orchestrate metastatic organotropism of breast cancer: implications for promising therapeutics.Journal of translational medicine · 2025Review
- Facts and Hopes of CD40 Agonists in Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.Expert opinion on emerging drugs · 2025Review
- IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity.Journal for immunotherapy of cancer · 2025Article
- In vivo armed macrophages curb liver metastasis through tumor-reactive T-cell rejuvenation.Nature communications · 2025Article
- Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence.Frontiers in pharmacology · 2025Review
- Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy.Frontiers in immunology · 2025Article
- Dynamic Neutrophil-to-Lymphocyte Ratio at 3-4 weeks of Intensity-Modulated Radiotherapy Combined with Normal Liver Volume Predicts Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma: A Retrospective Study.Journal of inflammation research · 2025Article
- Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages.Cancer biology & medicine · 2024Article
- Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.Bioengineered · 2024Article
Corrections and comments
- Commented on by
Authors and funding
36 authors at 4 institutions in 3 countries.
Marie SiwickiCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6330-8780
Nicolas A Gort-FreitasDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8614-4782
Marius MessemakerCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7179-0594
Ruben BillCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4674-2531
Jeremy GungabeesoonCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4505-3160
Camilla EngblomCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5090-4161
Rapolas ZilionisDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.
Christopher GarrisCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.
Genevieve M GerhardCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4144-3284
Anna KohlCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0040-4967
Yunkang LinCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9182-8158
Angela E ZouCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9709-3121
Chiara CianciarusoCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5635-5404
Evangelia BolliCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.
Christina PfirschkeCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9434-4485
Yi-Jang LinCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1850-4245
Cecile PiotCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7639-3662
John E MindurCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2212-3904
Nilesh TaleleEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2758-8599
Rainer H KohlerCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6269-6590
Yoshiko IwamotoCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-9092-2265
Sara I PaiDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Claudio deVitoDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-4966-1278
Thibaud KoesslerDepartment of Oncology, Geneva University Hospitals, Geneva, Switzerland.ORCID 0000-0001-9196-9076
Doron MerklerDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Alexander CoukosPrecision Oncology Center, Department of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
Alexandre WickyPrecision Oncology Center, Department of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland.ORCID 0000-0003-0967-5787
Montserrat FragaFaculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Christine SempouxInstitute of Pathology, University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1375-3979
Rakesh K JainEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7571-3548
Pierre-Yves DietrichDepartment of Oncology, Geneva University Hospitals, Geneva, Switzerland.ORCID 0000-0002-7375-6939
Olivier MichielinPrecision Oncology Center, Department of Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0828-4143
Allon M KleinDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8913-7879
Mikael J PittetCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, USA. mikael.pittet@unige.ch.ORCID 0000-0002-2060-4691
Harvard University · USUniversity of Geneva · CHUniversity of Lausanne · CHMassachusetts General Hospital · US
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MStrategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI SARTOR, MAUREEN AGNES · 2019 to 2023
$8.4MDissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7MCellular mechanisms by which exhausted T cell responses are restoredR01AI123349 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Thorsten Roman Mempel · 2017 to 2026
$4.5MIn vivo behavior of monocytes in resting and inflammatory conditionsR01AI084880 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI PITTET, MIKAEL · 2011 to 2020
$4.4MFAST-FNA immune cell profiling in HNSCCR01CA257623 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FAQUIN, WILLIAM CLAY, WEISSLEDER, MD, PHD, RALPH · 2021 to 2025
$3.3MReprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9MImaging of nanotherapeutic drug actionU01CA206997 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$2.9MSingle Cell Genome-Wide Myeloid Response Profiling in ImmunotherapyR01CA218579 · NCI · HARVARD MEDICAL SCHOOL · PI KLEIN, ALLON MOSHE, PITTET, MIKAEL · 2018 to 2022
$2.7MReengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2MImaging tumor associated macrophage (TAM) functionR01CA206890 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PITTET, MIKAEL, WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$1.9MAnalysis of scant cancer cells in fine needle aspiratesR33CA202064 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2016 to 2018
$1.3MNCI NIH HHS P01 CA240239NCI NIH HHS R01 CA206890NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA218579NCI NIH HHS R01 CA257623NCI NIH HHS R33 CA202064NCI NIH HHS R35 CA197743NCI NIH HHS U01 CA206997NCI NIH HHS U01 CA224348NHLBI NIH HHS F31 HL147364NIAID NIH HHS R01 AI084880NIAID NIH HHS R01 AI123349NIGMS NIH HHS T32 GM007753
Abstract
Immunotherapy is revolutionizing cancer treatment but is often restricted by toxicities. What distinguishes adverse events from concomitant antitumor reactions is poorly understood. Here, using anti-CD40 treatment in mice as a model of T
Indexed as
AnimalsCD40 AntigensCTLA-4 AntigenCytokinesHumansImmune Checkpoint InhibitorsImmunotherapyKupffer CellsLiverMice, TransgenicNeoplasmsNeutrophilsProgrammed Cell Death 1 ReceptorCD40 AntigensCTLA-4 AntigenCytokinesImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.